NEW YORK & MINNEAPOLIS--(BUSINESS WIRE)--In an announcement today, Mount Sinai School of Medicine (MSSM) and Medisyn Technologies, Inc. said they have identified new chemical classes of preclinical compounds that may eventually lead to the first effective management of toxic amyloid aggregation and accumulation in the brain— an abnormal biological process long suspected by many researchers to be a major culprit in the onset and progression of Alzheimer’s disease.
